This administration approach poses substantial clinical challenges: it is not only unfeasible for therapeutic applications, but systemic STING inhibition may also undermine antipathogen immunity and tumor immunosurveillance, potentially enhancing patients'vulnerability to infections and cancer [423–425]. The gene discussed is STING1; the disease is neoplasm.